NasdaqCM:BLTEPharmaceuticals
Belite Bio (BLTE) Completes Phase 3 DRAGON Trial Enrollment For Stargardt Treatment
Belite Bio (BLTE) recently announced the successful completion of the Phase 3 DRAGON clinical trial, which significantly focuses on treating Stargardt disease type 1. The company's share price increased by 17% over the last quarter, potentially boosted by this achievement and the financial infusion from a recent private placement that raised approximately $125 million. These developments might have reinforced investor confidence despite the broader market rally, including the Nasdaq reaching...